Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia

Blood

Volumn 95, Issue 3, 2000, Pages 790-794

  Panzer Grümayer, E Renate ^a   Schneider, Monika ^a   Panzer, Simon ^a   Fasching, Karin ^a   Gadner, Helmut ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; DISEASE COURSE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RISK ASSESSMENT;

EID: 0034141517     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.790.003k48_790_794     Document Type: Article

References (19)

1. Pui C-H. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 1998;5:292.
2. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80: 1717.
3. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2403.
4. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after one week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292.
5. Wassermann R, Galili N, Ito JH, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol. 1992;10:1879.
6. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet. 1994;343: 196.
7. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339:591.
8. Van Dongen JM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731.
9. Schrappe M, Reiter A, Sauter S, et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark [German]. Klin Padiatr. 1994;206:208.
10. Hettinger K, Fischer S, Panzer S, Panzer-Grümayer ER. Multiplex PCR for TCR delta rearrangements: a rapid and specific approach for the detection and identification of immature and mature rearrangements in ALL. Br J Haematol. 1998;102:1050.
11. Stolz F, Panzer S, Fischer S, Panzer-Grümayer ER. Oligoclonal IgH and TCRδ rearrangements persist in a recurrent ALL with one Igκ rearrangement as a clonal marker. Mod Pathol. 1999;12: 819.
12. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the Biomed-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110.
13. Ghali DW, Panzer S, Fischer S, et al. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias. Blood. 1995;85:2795.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1958;22:719.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn. 1958;53:457.
16. Cox D. Regression models and live tables. J R Stat Soc (B). 1972;34:187.
17. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol. 1989;7:1807.
18. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990;18: 273.
19. Nachman J, Sather H, Lukens J, et al. Intrathecal methotrexate is sufficient central nervous (CNS) prophylaxis for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid early response (RER) to BFM induction chemotherapy. Blood. 1995;86(suppl):265a.